A 52-year-old woman with colorectal cancer is being treated with 5-fluorouracil. Her oncologist adds leucovorin to the regimen. Which feature best distinguishes the pharmacological effect of leucovorin addition from the mechanism of 5-FU itself?

Question

Accepted Answer

A. Leucovorin restores the tetrahydrofolate pool, allowing thymidylate synthase inhibition to be more selective and prolonged. ## Leucovorin Rescue: Mechanism and Rationale

### Understanding the Paradox

**Key Point:** Leucovorin is a **reduced folate** (folinic acid, 5-formyl-THF) that **bypasses the DHFR block** caused by methotrexate, but it **enhances 5-FU efficacy** — this seems paradoxical but is mechanistically sound.

### Why Leucovorin Enhances 5-FU (Not Methotrexate Rescue)

**High-Yield:** The key is that 5-FU and leucovorin work on **different enzymes**:

1. **5-FU mechanism:** Converts to FdUMP → inhibits thymidylate synthase (TS)
2. **Leucovorin mechanism:** Provides THF cofactor → stabilizes the FdUMP–TS–THF ternary complex
3. **Result:** The ternary complex is more stable and longer-lasting, prolonging TS inhibition

### The Ternary Complex Formation

```mermaid
flowchart TD
  A["5-FU → FdUMP"]:::action --> B["FdUMP binds Thymidylate Synthase"]:::action
  C["Leucovorin → THF"]:::action --> D["THF binds to TS-FdUMP complex"]:::action
  B --> E["Ternary Complex: TS-FdUMP-THF"]:::outcome
  D --> E
  E --> F["Prolonged TS inhibition"]:::outcome
  E --> G["Increased dTMP depletion"]:::outcome
  G --> H["Enhanced cytotoxicity"]:::urgent
```

### Comparison: Leucovorin in Different Contexts

| Context | Drug | Leucovorin Role | Mechanism |
|---------|------|-----------------|----------|
| **Methotrexate toxicity** | MTX | Rescue / Antidote | Bypasses DHFR block, restores THF |
| **5-FU enhancement** | 5-FU | Synergist / Potentiator | Stabilizes TS-FdUMP-THF complex |
| **Net effect** | MTX | Reduces toxicity | Decreases drug effect |
| **Net effect** | 5-FU | Increases efficacy | Enhances drug effect |

**Clinical Pearl:** This is why 5-FU + leucovorin is a standard regimen (e.g., FOLFOX, FOLFIRI in colorectal cancer). Leucovorin is **not** a rescue agent here — it is a **potentiator**. The distinction is critical for exam success.

**Mnemonic:** **FLU** = **F**luorouracil + **L**eucovorin + **U**racil (or think "Flu shot" — 5-FU gets a boost from leucovorin).

[cite:KD Tripathi 8e Ch 65; Harrison 21e Ch 104]

Answer

B. Leucovorin acts as a competitive antagonist at the same enzyme target as 5-FU

Answer

C. Leucovorin directly inhibits thymidylate synthase like 5-FU does

Answer

D. Leucovorin enhances 5-FU activation by increasing orotate phosphoribosyltransferase activity

A 52-year-old woman with colorectal cancer is being treated with 5-fluorouracil. Her oncologist adds leucovorin to the regimen. Which feature best distinguishes the pharmacological effect of leucovorin addition from the mechanism of 5-FU itself?

Explanation

Practice similar questions